IVUS测定的血管尺寸对股腘动脉支架植入中期结局的影响
该回顾性研究纳入274例患者共335处股腘动脉原发病变,术前及支架植入成功后行IVUS评估,分析24个月支架通畅性的预测因素。结果显示24个月一期通畅率为73.2%,远端参考EEM面积增大与通畅性改善相关,而病变长度增加则降低通畅性;远端参考EEM面积29.0 mm²为最佳预测切点。
要点
- 远端参考EEM面积增大是24个月支架通畅的独立预测因素(OR 1.18)。
- 病变长度每增加单位,24个月通畅性下降(OR 0.89)。
- 远端EEM面积>29.0 mm²者24个月一期通畅率显著高于≤29.0 mm²者(83.7% vs 53.1%)。
核心结论
- 在IVUS评估远端血管面积较大的股腘动脉病变中,支架植入可作为合理治疗选择,中期结果可能可接受。
研究设计与样本
- 回顾性分析274例连续患者共335处原发股腘动脉病变,均在支架植入前后行IVUS评估。
- 平均年龄72.4±8.2岁,男性210例,平均病变长度13.2±9.8 cm。
主要发现
- 24个月随访期间18例(7%)患者死亡,286处病变中43处(15%)发生MALE(42例TLR和1例大截肢)。
- 一期通畅率12个月为82.5%(95%CI 78.1%~86.9%),24个月为73.2%(95%CI 67.9%~78.5%)。
- 多因素分析显示病变长度较长与通畅性下降独立相关(OR 0.89,95%CI 0.82~0.97,p<0.01)。
- 西洛他唑使用(OR 3.45,95%CI 1.10~10.78,p=0.03)和远端参考EEM面积增大(OR 1.18,95%CI 1.02~1.37,p=0.03)与中期支架通畅相关。
关键数值与推荐
- ROC曲线确定远端参考EEM面积29.0 mm²为预测24个月支架通畅的最佳切点(AUC 0.764)。
- 远端EEM面积>29.0 mm²者24个月一期通畅率为83.7%(95%CI 78.3%~89.2%),≤29.0 mm²者为53.1%(95%CI 42.9%~63.3%)(p<0.001)。
- ISR定义为双功超声峰值收缩期流速比>2.4。
- MALE定义为主要截肢或任何靶病变血运重建(TLR)。
临床怎么用
- 股腘动脉支架植入前可考虑行IVUS评估远端参考血管EEM面积,以辅助预测中期通畅性。
- 远端EEM面积较大的病变,支架植入的中期结果可能可接受。
- 病变长度较长时需预期中期通畅性可能下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: To identify intravascular ultrasound (IVUS) findings that predict midterm stent patency in femoropopliteal (FP) lesions. Materials and Methods: A retrospective analysis was undertaken of 335 de novo FP lesions in 274 consecutive patients (mean age 72.4±8.2 years; 210 men) who had IVUS assessment before and after successful stent implantation. The mean lesion length was 13.2±9.8 cm. The primary outcome was primary patency at 24 months, defined as freedom from major adverse limb event (MALE) and in-stent restenosis (ISR). MALE was defined as major amputation or any target lesion revascularization (TLR). ISR was defined by a peak systolic velocity ratio >2.4 by duplex ultrasonography. Logistic regression analyses were performed to identify independent predictors of stent patency at 24 months; the results are presented as the odds ratio (OR) and 95% confidence interval (CI). Receiver operator characteristic (ROC) curve analysis was performed to determine the optimal threshold for prediction of stent patency at 24 months. Results: Over the 24-month follow-up, 18 (7%) patients died and 43 (15%) of 286 lesions were responsible for MALE (42 TLRs and 1 major amputation). Primary patency was estimated at 82.5% (95% CI 78.1% to 86.9%) at 12 months and 73.2% (95% CI 67.9% to 78.5%) at 24 months. Multivariable analysis revealed that longer lesion length (OR 0.89, 95% CI 0.82 to 0.97, p<0.01) was an independent predictor of declining patency, while cilostazol use (OR 3.45, 95% CI 1.10 to 10.78, p=0.03) and increasing distal reference external elastic membrane (EEM) area (OR 1.18, 95% CI 1.02 to 1.37, p=0.03) were associated with midterm stent patency. ROC curve analysis identified a distal reference EEM area of 29.0 mm2 as the optimal cut-point for prediction of 24-month stent patency (area under the ROC curve 0.764). Kaplan-Meier estimates of 24-month primary patency were 83.7% (95% CI 78.3% to 89.2%) in lesions with a distal EEM area >29.0 mm2 vs 53.1% (95% CI 42.9% to 63.3%) in those with a distal EEM area ≤29.0 mm2 (p<0.001). Conclusion: In FP lesions with a larger distal vessel area estimated with IVUS, stent implantation can be considered as a reasonable treatment option, with the likelihood of acceptable midterm results.
引用
- Miki K, Fujii K, Tanaka T, et al. Impact of IVUS-Derived Vessel Size on Midterm Outcomes After Stent Implantation in Femoropopliteal Lesions. J Endovasc Ther. 2020. PMID: 31948376. doi:10.1177/1526602819896293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。